Gabapentin Tablet
Product Images NDC 70518-2912

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2912). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Gabapentin 800mg 70518 2912 01)

Label for Gabapentin 800 mg oral tablet, quantity 1, repackaged by RemedyRepack Inc. The label includes the NDC number 70518-2912-01 and shipping details for the manufacturer Ascend Labs, LLC, Montvale, NJ. The label instructs users to see the package insert for directions and provides storage temperature guidelines.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 800 mg oral tablets in a repackaged container labeled by RemedyRepack Inc. The label shows a quantity of 100 tablets and includes a QR code, NDC number 70518-2912-00, manufacturer Ascend Labs, and storage instructions. The label states Rx only and directs users to see the package insert for directions.*

FDA Label Image

Gabapentin Equation (Gabapentin Equation)

A formula for calculating creatinine clearance (CLCr) is shown, involving age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor for female patients (0.85). This text panel provides a pharmacokinetic calculation relevant to the drug Gabapentin.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over an 8-week period for placebo and 3600 mg/day gabapentin groups. The x-axis shows weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin group scores decrease steadily from baseline, while placebo group scores remain relatively stable.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph showing mean pain scores over 7 weeks for three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks from baseline through week 7; the y-axis shows mean pain scores from 0 to 10. The graph is divided into a 3-week dose titration period and a 4-week fixed dose period.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

Bar graph showing the proportion of responders with at least 50% reduction in pain score at endpoint in two controlled postherpetic neuralgia (PHN) studies. Study 1 compares placebo (PBO) at 12% to gabapentin 3600 mg (GBP 3600) at 29%. Study 2 compares placebo at 14% to gabapentin 1800 mg (GBP 1800) at 32% and gabapentin 2400 mg (GBP 2400) at 34%. Statistical significance is indicated with p-values (p < 0.01 and p < 0.001).*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot chart showing the percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis for Gabapentin across three studies labeled Study a, Study b, and Study c. Data points for each study are plotted at daily doses of approximately 600, 900, 1200, and 1800 mg, with Study a consistently having higher difference percentages compared to Studies b and c.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

Chemical structure of Gabapentin, an active pharmaceutical ingredient. The diagram shows a cyclohexane ring attached to side chains containing an amino group and a carboxylic acid group, representing the molecular arrangement of Gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.